Business
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"2024 Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million 2025 Financial Guidance: Total Revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million NOVATO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2024 and shared financial guidance for 2025. “We have created a next-generation rare disease company on a pathway to profitability with meaningful revenue growth from multiple global products and a series of potential new drug approvals,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “The major regulatory and clinical catalysts ahead of us this year are the pending PDUFA decision for our gene therapy to treat Sanfilippo syndrome, submission of our second gene therapy biologics license application in Glycogen Storage Disease Type Ia, readout of our pivotal Phase 3 results in osteogenesis imperfecta, and completion of enrollment in our Phase 3 trial in Angelman syndrome.\" Fourth Quarter and Full Year 2024 Selected Financial Data Tables and Financial Results Revenues (dollars in thousands), (unaudited) Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Crysvita Product sales$22,415 $18,379 $134,709 $75,697 Revenue in Profit-Share Territory 85,534 70,124 248,966 231,574 Royalty revenue in European Territory 7,473 5,612 25,849 20,783 Total Crysvita Revenue 115,422 94,115 409,524 328,054 Dojolvi 31,103 23,286 88,194 70,633 Evkeeza 10,374 2,102 32,162 3,642 Mepsevii 7,978 7,889 30,350 30,441 Other — — — 1,479 Total revenues$164,877 $127,392 $560,230 $434,249 Total RevenuesUltragenyx reported $165 million in total revenue for the fourth quarter of 2024, which represents 29% growth compared to the same period in 2023. Fourth quarter 2024 Crysvita revenue was $115 million, which represents 23% growth compared to the same period in 2023. This includes product sales of $22 million from Latin America and Turkey, which represents 22% growth compared to the sa...